Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
RESEARCH TOOLSreports
RCKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.25 - $28.73
Previous CloseN/A
Volume339.48K
Average Volume (3M)1.35M
Market Cap
$935.14M
Enterprise Value$1.53B
Total Cash (Recent Filing)$111.36M
Total Debt (Recent Filing)$41.45M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 07, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding106,629,700
10 Day Avg. Volume1,452,695
30 Day Avg. Volume1,349,293
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-215.43
Enterprise Value/Ebitda-6.19
Forecast
1Y Price Target
$39.79Price Target Upside363.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Rocket Pharmaceuticals News
PremiumCompany Announcements
Rocket Pharmaceuticals Advances Gene Therapy Pipeline
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe study in Danon Disease has a very high probability of achieving its co-primary endpoints based on the Phase I data.
Financial PositionRocket ended with $372M including ~$190M from a recent financing, supporting operations into 3Q:26.
Bears Say
Regulatory ChallengesCRL for Kresladi in leukocyte adhesion deficiency-1 (LAD-1) indicates challenges with FDA review.
---
Ownership Overview
34.67% Insiders
22.53% Mutual Funds
0.51% Other Institutional Investors
30.92% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $8.25 and its highest was $28.73 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Rocket Pharmaceuticals’s market cap is $935.14M.
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 57 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Feb 27, 2025. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.718 by $0.098.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -0.61.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 106,629,700 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.718. Following the earnings report the stock price went up 0.532%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Currently, no hedge funds are holding shares in RCKT
---
Rocket Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.79 (363.21% Upside)
$39.79 (363.21% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 700.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $533.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.13%
12-Months-Change
Fundamentals
Return on Equity
-54.14%
Trailing 12-Months
Asset Growth
-6.82%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
RCKT Stock 12 Month Forecast
Average Price Target
$39.79
▲(363.21% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering RCKT
1 Year
1 Year Success Rate
14/23 ratings generated profit
1 Year Average Return
+26.38%
reiterated a buy rating 11 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +26.38% per trade.
---